metricas
covid
Buscar en
Annals of Hepatology
Toda la web
Inicio Annals of Hepatology Body mass index and alcohol consumption are directly related with liver steatosi...
Información de la revista
Vol. 19. Núm. 6.
Páginas 697 (noviembre - diciembre 2020)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 19. Núm. 6.
Páginas 697 (noviembre - diciembre 2020)
Letters to the Editor
Open Access
Body mass index and alcohol consumption are directly related with liver steatosis. Results from a prospective study of patients referred for hyperferritinemia
Visitas
1331
Agustín Castiellaa,b,
Autor para correspondencia
agustincastiella@yahoo.es

Corresponding author at: Gastroenterology Service, Donostia University Hospital, Pº Dr Beguristain s/n., 20014 Donostia, Spain.
, Eva Zapataa,b, Iratxe Urretac, Leire Zubiaurrea,b, José Mª Alústizad, Pedro Otazuae, José Ignacio Emparanzac, on behalf of the Burnia Group 1
a Gastroenterology, Donostia University Hospital, Donostia, Spain
b Gastroenterology, Mendaro Hospital, Mendaro, Spain
c Clinical Epidemiology, Clinical Epidemiology Unit, CASPe, CIBER-ESP, DonostiaUniversity Hospital, Donostia, Spain
d Radiology, Osatek Donostia, Donostia, Spain
e Gastroenterology, Mondragon Hospital, Mondragon, Spain
Este artículo ha recibido

Under a Creative Commons license
Información del artículo
Texto completo
Bibliografía
Descargar PDF
Estadísticas
Texto completo
To the Editor,

Liver steatosis (LS) is often suspected in patients with hyperferritinemia (HF) and HF is a well-known risk factor for steatosis in patients with chronic liver disease [1]. Patients with a history of chronic alcohol consumption or features of MS often present with hyperferritinemia [2].

The objectives of this work were to study the body mass index (BMI) and alcohol consumption in a cohort of patients referred for HF in 6 hospitals from the Basque country, Spain, and to study the prevalence of hepatic steatosis determined by MRI in these patients [2].

We designed a prospective study of 312 consecutive patients with HF (>200 µg/L women; 300 µg/L men) to develop and validate a diagnostic algorithm for high iron overload based on laboratory and genetic variables [3]. Another objective of the study, and the aim of this work, was to study the prevalence of hepatic steatosis determined by MRI in these HF patients and the relationship with the body mass index (BMI) and alcohol consumption. MRI images were recorded with a 1.5-Tesla systems. BMI and alcohol consumption were determined in all the patients. Patients were classified as normal weight (BMI < 25.0 kg/m²), overweight (BMI ≥ 25.0 and ≤ 29.9 kg /m²), and obese (BMI ≥ 30.0 kg /m²). Alcohol consumption was classified: women<20 g/day and men<40 g day in the non-alcohol group (non-alcohol or mild consumption); women >20 g/day and men 40 g/day alcohol group (moderate-heavy drinkers) [2,4].

Three hundred and twelve (272 men) were included in the study. In 286 patients, a MR study for the presence of liver steatosis was performed. One hundred ninety six had no steatosis and 90 hepatic steatosis (31.47%). We have studied the relationship between LS and the different BMI and Alcohol groups from the HF patients of the study (Table 1).

Table 1.

Body mass index (BMI), alcohol consumption and liver steatosis (LS).

Study group (N=286)  Total  LS  % LS 
BMI<25 kg/m²  11  52  21.15 
BMI 25–30 kg/m²  23  105  21.90 
BMI >30 kg/m²  56  129  43.41 
Non-alcohol group (g/day)  43  196  21.94 
Alcohol group (g/day)  32  90  35.56 

Liver steatosis was more frequent in the BMI > 30 group-obesity (56/129 patients with LS; 43.41% of the group), and the results were statistically significant (p = 0.000). When we compared the groups by alcohol consumption (no alcohol-mild consumption group vs moderate-heavy drinkers) the differences were statistically significant for the second group for LS (p = 0.015) (Table 1).

In conclusion, BMI and alcohol consumption are both directly associated with the presence of liver steatosis in patients referred for hyperferritinemia in our country.

Conflict of interest

The authors have no conflicts of interest to declare.

Funding

The authors have no conflicts of interest to declare.

References
[1]
A. Licata, M.E. Nebbia, G. Cabibbo, G. Lo Iacono, F. Barbaria, V. Brucato, et al.
Hyperferritinemia is a risk factor for steatosis in chronic liver disease.
World J Gastroenterol, 15 (2009), pp. 2132-2138
[2]
A. Castiella, I. Urreta, E. Zapata, L. Zubiaurre, J.M. Alústiza, P. Otazua, et al.
Liver iron concentration in dysmetabolic hyperferritinemia: Results from a prospective cohort of 276 patients.
Ann Hepatol, 19 (2020), pp. 31-35
[3]
E. Zapata, A. Castiella, I. Urreta, J.M. Alustiza, E. Salvador, P. Otazua, et al.
Diagnos-tic algorithm for high iron overload: results from a prospective study of 312patients with hyperferritinemia.
J Hepatol, 64 (2016), pp. S296
[4]
P. Trombini, V. Paolini, S. Pelucchi, R. Mariani, E. Nemeth, Ganz, et al.
Hepcidinresponse to acute iron intake and chronic iron loading in dysmetabolic ironoverload syndrome.
Liver, 31 (2011), pp. 994-1000

Collaborating authors: Hospital de Mendaro: Leire Zubiaurre, Eva Zapata, Agustín Castiella, Arantxa Iribarren; Hospital Universitario Donostia: Leire Zubiaurre, Eva Zapata, Agustín Castiella, Arantxa Iribarren, Usua Mendarte, Luis Bujanda, Nerea Muro, Begoña Ibarra, M. Dolores de Juan, Iratxe Urreta, Jose I. Emparanza; Osatek Donostia: Jose M. Alústiza, Emma Salvador; Hospital de Mondragón: Pedro Otazua, Aitor de Juan; Hospital de Galdakao: Garazi Letamendi; Hospital de Cruces: Beatriz Arrizabalaga; Hospital del Bidasoa: Maria Luisa Rincón.

Copyright © 2020. Fundación Clínica Médica Sur, A.C.
Descargar PDF
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos